Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

October 20, 2017

Study Completion Date

October 20, 2017

Conditions
Macular Degeneration
Interventions
DRUG

Abicipar pegol

Abicipar pegol 2 mg administered to the study eye by intravitreal injection.

Trial Locations (18)

28387

Caroline Eye Associates, Southern Pines

32503

Retina Specialty Institute, Pensacola

33146

University of Miami, Coral Gables

33770

The Eye Institute of West Florida, Largo

33880

Center for Retina and Macular Disease, Winter Haven

34994

East Florida Eye Insititute, Stuart

44122

Cole Eye Institute, Cleveland Clinic, Cleveland

46290

Raj K. Maturi, MD, Indianapolis

53715

Davis Duehr Dean, Madison

84107

Rocky Mountain Retina Consultants, Salt Lake City

85296

Retinal Consultants of Arizona, Gilbert

90211

Retina Vitreous Associates Medical Group, Beverly Hills

91006

Win Retina, Arcadia

91107

California Eye Specialists Medical Group, Inc-Private Clinic, Pasadena

92093

Jacobs Retina Center, Shiley Eye Institute, UCSD, La Jolla

92647

Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach

02114

Massachusetts Eye & Ear, Boston

03801

Eyesight Ophthalmic Services, PA, Portsmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY